Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
Abroad (travel likely)RecruitingPHASE2
Conditions
Idiopathic Pulmonary Fibrosis · Idiopathic Pulmonary Fibrosis (IPF)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mannkind Corporation, Danbury, Connecticut, United States
Contact: Study coordinator (Senior Vice President, Therapeutic Area Head, Orphan Lung Dise, MD) · wfares@mannkindcorp.com · 203-796-3407Trial Management Group Inc, Windsor, Ontario, Canada